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INTRODUCTION: Marine organisms have in their 
constitution materials with a wide range of properties 
and characteristics inspiring their application within the 
biomedical field. One important example is fucoidan 
(Fu), an underexploited sulfated polysaccharide 
extracted from the cell wall of the brown seaweeds, with 
high solubility in water1. Fucoidan is composed of L-
fucose and glucuronic acid including sulfate groups and 
has important bioactive properties such as antioxidative, 
anticoagulant, anticancer and in the reduction of blood 
glucose1,2. In this work, the biomedical potential of 
fucoidan was assessed by processing modified fucoidan 
(MFu) into microparticles by photocrosslinking using 
superhydrophobic surfaces and visible light3,4. 
Biological performance on the developed constructs 
using human pancreatic beta cells is currently under 
investigation.  
METHODS: To design the materials structures, 
fucoidan was modified by methacrylation reaction3. 
Briefly, Fu aqueous solution 4% w/v was mixed with 
methacrylated anhydride (MA) in volume of 12% v/v at 
50ºC to react for 6h. Further, MFu particles with and 
without insulin (0.5% w/v) were produced by pipetting 
a solution of 5% MFu v/v with triethanolamine and 
eosin-y (photoinitiators) onto superhydrophobic 
surfaces4 (Fig. 1A) and then photocrosslinking using 
visible light4. MFu and developed particles were 
characterized using 1HNMR, turbidimetry and SEM to 
assess their chemistry and morphology, respectively. 
Moreover, the insulin release was evaluated in 
phosphate buffered saline (PBS) solution at pH 7and 
simulated intestinal fluid (SIF) at pH 5. The ability of 
the developed materials to support adhesion and 
proliferation of cells was assessed by suspension culture 
of human pancreatic cells 1.1B4 (3.5x105 cells/ml) in 
contact with MFu microparticles during up to 7 days. 
RESULTS: The chemical modification performed on 
Fu was confirmed by the presence of vinyl and 
additional methyl peaks in the 1HNMR of modified 
fucoidan, not present in Fu spectrum. Methacrylated 
fucoidan was obtained with a methacrylation degree of 
17%. The produced fucoidan particles have round shape 
and average diameter of 1.53 mm (Fig. 1B). The insulin 
release in PBS and SIF demonstrate that the particles 
can release insulin in a sustained manner under the 
studied period. It seems that the insulin release is slower 
for SIF (pH5, Fig. 1C), than for PBS. The biological 
tests regarding the culture of pancreatic beta cells 
demonstrate that cells show a round-like shape and tend 
to form pseudo-islets during the culture period studied 
(Fig. 1D). 
         
Fig. 1: A) Scheme of modified fucoidan particles 
production, B) modified fucoidan-particles, C) insulin 
release profile and D) confocal microscopy images of 
1.1B4 cells seeded onto MFu after 7 days in culture; 
staining of actin (red) and nuclei (blue). 
 DISCUSSION & CONCLUSIONS: This work 
demonstrates the successful production of fucoidan-
based-microparticles through the methacrylation of 
fucoidan, using visible light and superhydrophobic 
surfaces. The covalent crosslinking methacrylated 
fucoidan through visible light represents a promising 
method to obtain biocompatible fucoidan particles with 
a uniform round shape. The obtained insulin release 
profiles are sensitive to different pH (pH7 and pH5), 
mimicking the normal physiological pathway for insulin 
release. Furthermore, the results suggest these systems 
could be used for treatment of type I diabetes mellitus as 
they sustain beta cells viability and proliferation. The 
response also suggested, that the MFu particles could be 
a good candidate as drug delivery vehicles for the 
diabetes mellitus treatment.  
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